Form 4: Aurinia Pharmaceuticals Director Sells Shares After RSU Vesting

A director at Aurinia Pharmaceuticals sold 4,557 shares to cover tax obligations after the vesting of restricted stock units.

Summary

• Jeffrey Allen Bailey, a director at Aurinia Pharmaceuticals, acquired 17,913 shares of common stock on November 8, 2024, through the vesting of restricted stock units (RSUs).
• Following the vesting, Mr. Bailey sold 4,557 shares on November 11, 2024, at an average price of $8.43 per share to cover tax withholding obligations.
• The sale resulted in Mr. Bailey holding 13,356 shares of common stock directly.
• The RSUs vested one year from the date of grant and have no expiration date.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction related to the vesting of equity compensation for a company director. Such transactions are common and are typically disclosed to the SEC.

Comparison to Industry Standards

• The sale of shares to cover tax obligations after RSU vesting is a standard practice across publicly traded companies.
• Many companies use RSUs as part of their compensation packages for directors and employees.
• The price range of $8.37 to $8.47 is within the normal range of price fluctuations for a stock.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale of shares by a director to cover tax obligations.

Key Dates

Keywords

Aurinia Pharmaceuticals, insider trading, stock sale, restricted stock units, RSU, director, share transaction